Please assess the completion status of the following clinical trial:

Trial Title: Developing World Study for RotaTeq™ (V260-015)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 4 weeks through 12 weeks at Dose 1~* Parent able to understand study procedures and give consent~Exclusion Criteria:~* Clinical evidence of active gastrointestinal disease~* Subjects who are currently or expected to participate in other studies of investigational products during the 6 weeks after receiving the last dose of RotaTeq™/placebo

- Gender: ALL
- Minimum Age: 4 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): RotaTeq™
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).